Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines.
10.3349/ymj.2013.54.2.271
- Author:
Yo Han JANG
1
;
Baik Lin SEONG
Author Information
1. Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Seoul, Korea. blseong@yonsei.ac.kr
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
Influenza live attenuated vaccine;
cross-protection;
cold-adaptation;
universal vaccine
- MeSH:
Adaptive Immunity;
Antigens, Viral/immunology;
*Cross Protection;
Genome, Viral;
Humans;
Immunity, Innate;
Influenza Vaccines/*immunology/therapeutic use;
Influenza, Human/*prevention & control;
Orthomyxoviridae/genetics/immunology;
Vaccines, Attenuated
- From:Yonsei Medical Journal
2013;54(2):271-282
- CountryRepublic of Korea
- Language:English
-
Abstract:
The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.
